Alaunos Therapeutics Inc. is a biotechnology company focused on the development of innovative cell therapies to treat various forms of cancer. Committed to advancing the field of oncology, its primary function is to harness the power of the immune system by engineering T-cells to target and eradicate cancer cells. Key features of Alaunos Therapeutics' approach include cutting-edge technologies like its proprietary library of TCRs (T-cell receptors) which are designed to enhance precision in targeting cancerous mutations. This capability positions the company at the forefront of immunotherapy research and development, particularly in its impact on solid tumors and hematological malignancies. Operating within a highly specialized industry, Alaunos Therapeutics plays a critical role in the biomedical sector by contributing to the development of next-generation treatments that aim to provide new hope for patients whose options may be limited by traditional therapies. Headquartered in the United States, it continues to collaborate with leading institutions to push the boundaries of cancer treatment through innovative scientific solutions.